Abstract
One of the most serious possible consequences of cancer therapy is the development of a second cancer, especially leukemia. Several distinct subsets of therapy-related leukemia can be distinguished currently. These include classic therapy-related myeloid leukemia, leukemia that follows treatment with agents that inhibit topoisomerase II, acute lymphoblastic leukemia, and leukemias with 21q22 rearrangements or inv(16) or t(15;17). These types of leukemia are discussed in detail in this article.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Acute Disease
-
Antineoplastic Agents / adverse effects
-
Bone Marrow Transplantation / adverse effects
-
Humans
-
Leukemia, Myeloid / etiology*
-
Leukemia, Myeloid / genetics
-
Myelodysplastic Syndromes / etiology*
-
Myelodysplastic Syndromes / genetics
-
Neoplasms, Second Primary / etiology*
-
Neoplasms, Second Primary / genetics
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
-
Radiotherapy / adverse effects